ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RVMD
BIIB (74) ARGX (63) BNTX (52) MRNA (60) ⌘ Pro Terminal →

Revolution Medicines Inc. (RVMD) — RQD Stock Rating Cockpit

$191.31 +0.55% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $191.14

Revolution Medicines Inc. (RVMD) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY) →
ROARABLE D+ • SELL / AVOID Cap $40.78B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RVMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RVMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Revolution Medicines Inc. (NASDAQ: RVMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $191.31 (+0.55% 1D, market cap $40.78B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RVMD ranks #222 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RVMD compare to BIIB and ARGX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RVMD carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.6%. By comparison, BIIB (Biogen Inc.) holds a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B) and ARGX (argenx SE) posts a C grade (63/100 RQD, P/E 32.8x, ROIC 9.9%, cap $55.72B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RVMD?
▼

Per RVMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628171), Revolution Medicines Inc. generated $0 in revenue, -$1.13B in net income, and -$913.7M in free cash flow against $2.35B in total assets and $325.4M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $191.14 (-0.09%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 55/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.5% avg 90D alpha vs SPY • 51.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510055
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk B-
Cash (9)Whales (13)SEC (16)Macro (12)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-1.3% Base Target
$236 Bull$189 Base$147 Bear
📬 FREE RVMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RVMD)Realized 20D OHLCV Swing Band: ±9.5%
Deterministic 5-Pillar Attribution (55/100 Composite)
🔍 WHY RVMD SCORES 55/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (29% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (24% of score)

20D Institutional Volume Accumulation (±9.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
47
Grade D$188.44+4.3% Next Q
Q2 (-2Q)
50
Grade C-$196.55-5.3% Next Q
Q3 (-1Q)
52
Grade C-$186.22+2.7% Next Q
Current
55
Grade D+$191.31-0.5% Hist 90D α
Trajectory: D (47) → D+ (55)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RVMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 55/100 (D+) score, RVMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Dilution Drag (+1.92% YoY Shares) — any gross margin slip below 15.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($198.41) or 200D SMA ($156.72) invalidates the momentum regime and cuts Target Base ($188.73) toward Bear Floor ($147.21).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RVMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RVMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 55%NO 45%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
47.830 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE80% OF RANGE
L: $57$191.31H: $224
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 9 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 18 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on RVMD

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (45)

-28.6% ROIC with 42.0% gross margin and -2.24% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (50)

18/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like RVMD
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RVMD)

  • ✓Walkthrough of RVMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RVMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.35%📐 HORIZONTAL RANGE
2026-11-02O $188.7H $191.3L $188.7C $191.3VOL 1.32M
RES: $249.5SUP: $175.9SMA50: $198.4SMA200: $156.7
$234.6$191.9$149.1$106.4$63.61RES $249.5SUP $175.9$191.32026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RVMD Butterfly Map → + Track RVMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
26.2%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RVMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RVMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RVMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVMD)

Health Care Rank #222 of 1016 ⚔️ BIIB vs RVMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RVMD vs. BIIB, ARGX, BNTX, MRNA)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Revolution Medicines Inc. (RVMD) ranks #222 by composite RQD confidence (55/100, grade D+) and #47 by equity capitalization ($40.78B). Within this direct 5-issuer industry benchmark cohort, BIIB leads on earnings valuation at 28.5x trailing P/E, while ARGX leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BIIB currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RVMD at 55/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RVMD ACTIVE
Revolution Medicines Inc.
D+ 55/100 — — -28.6% +0.55% $40.78B Benchmark Subject
BIIB
Biogen Inc.
B 74/100 28.5x 75.7% 6.4% +1.59% $36.90B /biib-vs-rvmd →
ARGX
argenx SE
C 63/100 32.8x — 9.9% -0.56% $55.72B /argx-vs-rvmd →
BNTX
BioNTech SE
D+ 52/100 32.8x — 9.9% -1.08% $22.39B /bntx-vs-rvmd →
MRNA
Moderna Inc.
C- 60/100 — 55.3% -34.1% -0.47% $88.93B /mrna-vs-rvmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001628171

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Revolution Medicines Inc. (RVMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$1.13B, operating cash flow of -$897.7M, and free cash flow of -$913.7M (-60.9% YoY). On the balance sheet, RVMD closed FY2025 with $2.35B in total assets against $325.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$1.13B -$897.7M -$913.7M $2.35B $325.4M
FY2024 (FY) 2024-12-31 $0 -$600.0M -$557.4M -$567.7M $2.56B $131.9M
FY2023 (FY) 2023-12-31 $11.6M -$436.0M -$350.6M -$351.1M $22.43B $5.25B

3. RVMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Revolution Medicines Inc. (NASDAQ: RVMD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $191.31 (+0.55% 1D, market cap $40.78B). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, RVMD ranks #222 in composite RQD confidence.

How does RVMD compare to BIIB and ARGX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), RVMD carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.6%. By comparison, BIIB (Biogen Inc.) holds a B grade (74/100 RQD, P/E 28.5x, ROIC 6.4%, cap $36.90B) and ARGX (argenx SE) posts a C grade (63/100 RQD, P/E 32.8x, ROIC 9.9%, cap $55.72B). Among the 5-stock peer group, BIIB leads on earnings multiple (28.5x) while ARGX leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RVMD?

Per RVMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001628171), Revolution Medicines Inc. generated $0 in revenue, -$1.13B in net income, and -$913.7M in free cash flow against $2.35B in total assets and $325.4M in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RVMD trading relative to its 50-day, 200-day, and 52-week technical levels?

RVMD last traded at $191.31 (+0.55% on volume of 1,100,758 shares), positioning the stock -3.58% below its 50-day simple moving average ($198.41) and +22.07% above its 200-day simple moving average ($156.72). Across its 52-week range of $56.66 to $224.31, RVMD sits at the 80.3% percentile with a 14-day RSI of 47.8 (NEUTRAL RANGE) and an implied next-earnings move of ±9.5% ($173.14 to $209.48).

RVMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RVMD stock right now?

Revolution Medicines Inc. (RVMD) currently earns a Roarable Rating of D+ (Sell — SELL) with 55/100 RQD Confidence. Stretched risk/reward at current multiples (-29% return on capital) under elevated 10-year interest-rate pressure.

What is RVMD's 12-month price target and RQD AI Jury consensus?

RVMD's 12-month base price target is $188.73 (range $147.21 to $235.53), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RVMD RQD Cockpit RVMD 12M Forecast RVMD Earnings & Move RVMD Dividends & DRIP RVMD Insiders & 13F RVMD Whale Options RVMD Profit Sankey RVMD News & Why
ROARABLE RATING BRIEF • RQD 55/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RVMD — Revolution Medicines Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:11:38Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD rating is 55 out of 100, a letter grade of D+, with the verdict label "Roarable Sell — Weak Fundamentals / Trim" (per the Roarable RQD rating). The score is built from five pillars:

  • Fundamental Cash Engine: 9 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -28.6% and FCF yield of -2.24%. Both metrics indicate the business is not currently generating returns on invested capital or free cash flow, which is the weakest-scoring area for an investor focused on earnings power.
  • Whale 13F Flow: 13 / 20. This pillar reflects institutional accumulation and options positioning. It is a mid-range score, with no holder-level detail provided in the source data to explain its drivers.
  • Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, indicating limited insider signal support.
  • Macro Regime Fit: 12 / 20. Per the Roarable RQD rating, this reflects Beta of 1.07 and sector sensitivity. Beta slightly above 1.0 implies somewhat higher price sensitivity than the broad market.
  • Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, this reflects Altman Z of 26, Piotroski F of 5/9, and Debt/Equity of 0.19. This is the strongest pillar, indicating the balance sheet is less of a concern than operating cash generation.

For a prospective investor evaluating the stock today, the rating points to a clear tension: the balance sheet metrics are comparatively supportive, while the cash-generation, insider, and returns metrics are weak. Upside drivers would need to come from improvement in cash generation or returns on capital, which the source data does not project. Valuation tradeoffs are visible in the fact that forward P/E is 34 while trailing EPS is negative (per the Market Data section), meaning current pricing relies on expectations not captured in the reported figures. This is an analytical summary, not personalized financial advice.

Business

Revolution Medicines Inc. (RVMD) is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry (per the company profile). The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M for FY 2025 and FY 2024 and $11.6M for FY 2023 (per the SEC financials). Market capitalization is $40.8B (per the company profile).

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-1182.4M$-1131.0MN/A$-913.7M$383.7M$325.4M
FY 2024$0.0M$-689.5M$-600.0MN/A$-567.7M$543.1M$131.9M
FY 2023$11.6M$-487.2M$-436.0MN/A$-351.1MN/A$5248.6M

Per the SEC financials, the company reported operating losses in each period shown, and reported margins are 0% for gross, operating, and net (per the Market Data section). Per the Roarable RQD rating, ROIC is -28.6% and the Altman Z-Score is 26, with a Piotroski F-Score of 5/9. Debt/Equity is 0.19 (per the Roarable RQD rating). Reported debt declined from $5248.6M in FY 2023 to $325.4M in FY 2025 per the SEC financials, while cash was $383.7M at FY 2025 year-end.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items were published covering RVMD, all tagged with a YELLOW signal light under the MARKET WIRE label. Headlines reference market action, a 7.41% move on Oct 20 (per TradingKey), a report describing the company as "Its Already The Most Advanced RAS Company And There's More To Come" (per Stocks Down Under), and a question about whether the stock is a "millionaire-maker" (per The Motley Fool). The news summaries are generic and do not provide specific catalyst details such as trial results, approvals, or partnerships. Risk watch items are not specified in the source data. The butterfly supply-chain graph contains no proprietary signals (per the Butterfly Supply-Chain Graph).

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links or proprietary signals. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data. Sector classification is Health Care (per the company profile).

Open Questions

  • What specific products or pipeline assets generate the company's expected future revenue, given reported revenue of $0.0M for FY 2025 and FY 2024?
  • What is the basis for the 34x forward P/E when trailing EPS is -5.28?
  • What drove the decline in reported debt from $5248.6M in FY 2023 to $325.4M in FY 2025, and what is the current debt structure?
  • What institutional and insider holdings exist, given that the holders section contains no data?
  • What is the company's cash runway given FY 2025 free cash flow of $-913.7M against year-end cash of $383.7M?

RVMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Revolution Medicines Inc. (RVMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RVMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RVMD Bull vs. Bear Conversation Board — What's Your Call at $191.31?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RVMD 🐻 50% BEARISH CONVICTION
1. Pick Your Side on RVMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $205.49 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RVMD (D+ • RQD 55/100) a Buy at $190.27?

Welcome to the RVMD (Revolution Medicines Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $159.83 (-16.0%)
Spot @ $190.27

Pump the brakes on RVMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RVMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Revolution Medicines Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $235.93 (+24.0%)
Spot @ $190.27

RVMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RVMD, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $190.27 (52-wk range $56.66 - $224.31), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%